XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets
 6 Months Ended
Jun. 30, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets
Intangible assets

The following table summarizes the Company's intangible assets:
(In millions)
Currently marketed products
 
IPR&D
 
Other intangible assets
 
Total
June 30, 2018
 
 
 
 
 
 
 
Gross acquired intangible assets
$
29,731.9

 
$
5,112.9

 
$
825.7

 
$
35,670.5

Accumulated amortization
(5,167.8
)
 
—

 
(392.2
)
 
(5,560.0
)
Intangible assets, net
$
24,564.1

 
$
5,112.9

 
$
433.5

 
$
30,110.5

 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
Gross acquired intangible assets
$
31,973.5

 
$
5,113.9

 
$
835.9

 
$
37,923.3

Accumulated amortization
(4,549.2
)
 
—

 
(328.0
)
 
(4,877.2
)
Intangible assets, net
$
27,424.3


$
5,113.9


$
507.9


$
33,046.1



Other intangible assets are comprised primarily of royalty rights and other contract rights associated with Baxalta, Dyax Corp. (Dyax), and NPS Pharmaceuticals Inc. 

Activities in the net book value of intangible assets for the six months ended June 30, 2018 and 2017 are as follows: 
(In millions)
2018
 
2017
As of January 1,
$
33,046.1

 
$
34,697.5

Reclassification to assets held for sale
(1,598.5
)
 
—

Measurement period adjustments
—

 
(1,398.9
)
Amortization charged
(941.6
)
 
(798.1
)
Foreign currency translation
(256.7
)
 
953.8

Contribution to JV
(163.7
)
 
—

Impairment
(10.0
)
 
(20.0
)
Other
34.9

 
—

As of June 30,
$
30,110.5

 
$
33,434.3

 

Measurement period adjustments included in the six months ended June 30, 2017 related to the acquisition of Baxalta.

During the six months ended June 30, 2018, the Company contributed distributions rights for certain products to a joint venture formed by the Company. Upon the contribution, the net carrying value ($163.7 million) related to those products was recorded within Investments in these Unaudited Consolidated Balance Sheets.

For further details regarding the reclassification of Intangible assets to assets held for sale, refer to Note 4, Dispositions and Assets Held for Sale.

The Company reviews its amortized intangible assets for impairment whenever events or circumstances suggest that their carrying value may not be recoverable. Unamortized intangible assets are reviewed for impairment annually or whenever events or circumstances suggest that their carrying value may not be recoverable.

Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products. The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:

(In millions)
Anticipated future amortization
2018 (remaining six months)
$
857.7

2019
1,734.8

2020
1,591.0

2021
1,527.8

2022
1,495.4

2023
1,457.1